Price Chart
Key Statistics
Market Cap(EOD)190.27M
Enterprise Value187.63M
P/E Ratio (TTM)-8.60
P/B Ratio (TTM)5.86
P/S Ratio (TTM)9.90
Earnings Yield (TTM)-11.62%
ROE (TTM)-79.74%
ROIC (TTM)-44.58%
Net Profit Margin (TTM)N/A
Dividend Yield (TTM)N/A
Payout Ratio (TTM)N/A
Debt/Equity (TTM)0.21
About MediWound Ltd.
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.